AIDS AWARENESS: Top results for hepatitis C drug
THE FDA HAS approved Harvoni, a new drug that is up to 99% effective in treating chronic hepatitis C virus (HCV) genotype 1 infection, providing a major improvement in treatment for people living with the disease. In clinical trials, 94% of those who ...
New York Daily News - Wed, 26 Nov 2014 01:00

Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected ...
7thSpace Interactive (press release) - Tue, 25 Nov 2014 15:48



New Drug Can Cure Hepatitis C – If Only We Could Afford It
Just 5 years ago the cure rate for most patients in the US was about 50%. Now with Sovaldi, made by Gilead Sciences Inc. of California and approved by the FDA last December, the latest Hep C regimen is making therapy shorter, more tolerable, and the ...
West Virginia Public Broadcasting - Mon, 24 Nov 2014 13:00

EMA recommends two AbbVie treatments for hepatitis C
PMLiVE - Mon, 24 Nov 2014 04:08

Hep C wars heat up as AbbVie scores likely EU approval for Harvoni challenger
BioPharma Dive - Mon, 24 Nov 2014 07:00

3 Simple Reasons Doctors May Stick With Gilead Sciences Instead of AbbVie
Nasdaq - Tue, 25 Nov 2014 08:41

Despite Recent Hiccup, Gilead Is Still A Blue Chip Gem (GILD)
Seeking Alpha - Tue, 25 Nov 2014 07:45

Drug prices expected to rise nearly 12% this year
FierceHealthFinance - Mon, 24 Nov 2014 18:48

Costs of New Treatments for Hepatitis C Infection
In the acquisition of Pharmasset by Gilead for $11 billion, these assets were estimated at only $74.8 million.2 Despite 3 hepatitis C virus (HCV) drugs in development at Pharmasset (with only $62.4 million attributed to sofosbuvir development in 2009 ...
JAMA: The Journal of the American Medical Association - Tue, 25 Nov 2014 13:11

Effective drugs for carriers of hepatitis C not included in health basket
Hepatitis C carriers -- the majority of them immigrants from the former Soviet Union -- are a ticking bomb, as there are drugs that cure the disease but they are not in the basket of health services, according to experts who spoke at the Knesset ...
Jerusalem Post - Tue, 25 Nov 2014 07:11

Age Matters: Understanding a hepatitis C diagnosis
Roanoke Times (blog) - Mon, 24 Nov 2014 21:03



State advisory board recommends Hep-C drug for late-stage patients only
The Drug Utilization Review Board said it would recommend Medicaid coverage for a medication dubbed Harvoni only for patients who are in the later stages of hepatitis C or have other complicating issues, such as an illness like HIV or liver transplant.
Albany Times Union - Thu, 20 Nov 2014 22:45

France pegs Gilead hepatitis C drug at "lowest price in Europe"
Reuters - Thu, 20 Nov 2014 05:23

France strikes big hep C treatment deal for Gilead's Sovaldi
FiercePharma - Thu, 20 Nov 2014 08:25

At The Crossroads, Part 4: New Hep C Drugs Promise A Cure, For A Big Price
Rhode Island Public Radio - Thu, 20 Nov 2014 03:15

Hep C Drugs Cost FL Medicaid $30M So Far
WUSF News - Wed, 19 Nov 2014 08:05



Costly Hep C Drugs Help Drive Spending Jump
Several factors are driving the spending spike, including the introduction of expensive new hepatitis C drugs and fewer drug patent expirations than in previous years, the report found. Such expirations typically lead to savings as cheaper generics ...
WebMD - Wed, 19 Nov 2014 22:45

Drug spending tops $1 trillion on hepatitis C, cancer therapies: study
Reuters - Wed, 19 Nov 2014 20:52

So long, patent cliff. Hello, hep C and cancer. Welcome to $1.3T in global ...
FiercePharma - Thu, 20 Nov 2014 07:14

US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark
BioPharma Dive - Thu, 20 Nov 2014 06:48



Europe gives green light to AbbVie hepatitis C drugs, others
LONDON (Reuters) - European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of ...
Reuters - Fri, 21 Nov 2014 04:25

EMA Panel Backs Exviera, Viekirax for Chronic Hepatitis C
Medscape - Fri, 21 Nov 2014 13:11

AbbVie (ABBV) Hepatitis C Drugs Win The Nod Of European Regulators
Bidness ETC - Sat, 22 Nov 2014 04:56

AbbVie gets an EU green light for its next-gen hep C treatment
FierceBiotech - Fri, 21 Nov 2014 05:19

The dirty motivation behind Gilead's hepatitis C agreement
Up to 150 million people worldwide suffer from chronic hepatitis C, which attacks the liver and, if left untreated, can lead to cirrhosis and cancer. Complications related to hepatitis C claim 500,000 lives annually. A major hurdle to treating the ...
Al Jazeera America - Thu, 20 Nov 2014 23:03


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014